I. Definition & Classification

A hiatal hernia (HH) is defined as an abnormal protrusion of abdominal viscera—most commonly gastric tissue—through the esophageal hiatus of the diaphragm into the posterior mediastinum. Accurate classification is essential for risk stratification and management planning.

According to the Los Angeles Classification and updated consensus from the American Society for Gastrointestinal Endoscopy (ASGE), the European Hernia Society (EHS), and the American College of Gastroenterology (ACG), HHs are categorized as follows:

• Type 1 (Sliding Hiatal Hernia):
  The most common variant (~95% of cases). Characterized by dynamic displacement of the gastroesophageal junction (GEJ) and a portion of the gastric cardia above the diaphragm, often伴随着 loss of the acute angle of His and impaired lower esophageal sphincter (LES) function. The herniated segment reduces spontaneously or with positioning changes.
• Type 2 (Paraesophageal Hiatal Hernia):
  The GEJ remains in its anatomical position at the diaphragm, while a portion of the gastric fundus herniates alongside the esophagus into the mediastinum. This type carries significant risk for complications due to potential volvulus or vascular compromise.
• Type 3 (Mixed HH):
  Combination of Type 1 and Type 2 features—both GEJ and gastric fundus are herniated simultaneously.
• Type 4:
  In addition to stomach, other abdominal organs (e.g., colon, spleen, small bowel) may herniate into the mediastinum. Associated with higher morbidity and emergent presentation risk.

Epidemiologic Note: Prevalence increases dramatically with age: <10% in individuals <50 years vs >60% in those >70 years (JAMA Intern Med, 2020). Obesity (BMI >30), smoking, and connective tissue disorders are independent risk factors.

II. Pathophysiology & Clinical Implications

HHs contribute to gastroesophageal reflux disease (GERD) pathogenesis via several mechanisms:

• Mechanical disruption of the intrinsic LES complex
• Reduced intraluminal pressure at the GEJ due to diaphragmatic sling detachment
• Impaired clearance of refluxate due to loss of esophagogastric junction competence
• Increased transient LES relaxations (TLESRs) in Type 1 HH

Type 2–4 hernias are not strongly associated with acid exposure but pose unique mechanical risks:

• Gastric volvyllus (organoaxial or mesenteric axial)
• Ischemia from vascular compromise (e.g., gastric wall necrosis)
• Esophageal obstruction or dysphagia
• Chronic blood loss from mucosal breaks (Mallory–Weiss tears, Cameron ulcers)

Clinical pearl: Up to 50% of Type 1 HH patients are asymptomatic. Symptoms—when present—are often indistinguishable from non-HH GERD: heartburn, regurgitation, epigastric pain. Atypical presentations include retrosternal pressure, globus sensation, recurrent aspiration pneumonia, or iron-deficiency anemia (from chronic mucosal bleeding in large HHs).

III. Diagnostic Evaluation: When and How?

Principle: Only investigate if results will change management
— ACG Clinical Guideline (2022), Am J Gastroenterol

Imaging Guidance:

• CT chest/abdomen is reserved for acute presentations (e.g., severe chest pain, vomiting, signs of obstruction or ischemia). A “midline gastric bubble above the diaphragm” is suggestive. CT can identify Type 4 hernias with colon involvement and assess viability.
• MRI is rarely used due to motion artifacts but may be considered in research settings.

IV. Management: Evidence-Based Recommendations (ACG, SAGES, EHS 2021–2023)

A. Asymptomatic HHs

• Type 1 HH without GERD symptoms:
  Do not treat. No evidence that prophylactic intervention alters long-term outcomes (NNT for surgery >500; high complication risk). Surveillance only if patient anxiety or incidental finding during bariatric workup.
• Paraesophageal HH (Types 2–4) without symptoms:
  Individualize decision-making.
  • ACG Guideline (2022): “We conditionally recommend against routine elective repair in asymptomatic Type 2–4 HH due to low short-term complication rates (<1% annually), but strongly consider repair in patients with comorbidities allowing long follow-up, or those at high risk for volvulus (e.g., young patients, large hernia >5 cm, history of transient obstruction).”
  • SAGES Guidelines (2023): Repair strongly considered if ≥5 cm, age <75 y/o, good functional status, and available long-term surveillance.

Key Insight: Annual complication rates for asymptomatic paraesophageal HHs are ~0.8%—lower than previously assumed (Surg Endosc, 2021). Shared decision-making is critical.

B. Symptomatic HH

• Type 1 with reflux symptoms unresponsive to maximal medical therapy (e.g., twice-daily PPI for ≥3 months):
  Antireflux surgery (ARS) is indicated.
  • Laparoscopic Nissen fundoplication remains gold standard (success rate >90% at 5 years).
  • Partial wrap (Toupet, Dor) preferred in patients with pre-op dysmotility or esophageal hypomotility on manometry (ACG, 2022; meta-analysis Ann Surg, 2020).
• Type 2–4 with symptoms (dysphagia, chest pain, anemia, nausea/vomiting):
  Surgical repair is strongly recommended, regardless of reflux presence. Indications expand beyond acid control to prevent volvulus.

Note: In patients with both HH and Barrett’s esophagus, ARS may reduce progression risk—though PPIs remain first-line for metaplasia surveillance (Gastroenterology 2023;164:57–70).

C. Surgical Repair Technique

• Stepwise approach:
  1. Reduction of herniated contents (avoid gastric volvulus during mobilization)
  2. Hiatal dissection to achieve >1 cm of intra-abdominal esophagus
  3. Crural closure with non-absorbable suture (e.g., 3-0 Prolene)
  4. Fundoplication (Nissen/Toupet preferred over Dor in HH)
• Mesh use: Avoid synthetic mesh unless recurrent HH or large defect (>3–4 cm). EHS guidelines warn against routine mesh due to infection/fistula risk (Surg Endosc, 2021).

D. Incidental HH Discovery During Bariatric Surgery

• Conditional recommendation for repair during the index procedure:
  • Prevents future complications (especially in sleeve gastrectomy where residual stomach anatomy may predispose to HH)
  • Does not increase perioperative risk significantly when performed laparoscopically (Obes Surg, 2020;30:1485–1492)
• Timing: Repair during Roux-en-Y or sleeve gastrectomy is preferred over staged repair—reduces cumulative anesthesia risk and patient anxiety.

E. Medical Management Considerations

• PPIs remain first-line for Type 1 HH with GERD: do not reduce dose based on HH presence alone
• H2RAs lack efficacy in moderate-severe GERD with HH
• Prokinetics (e.g., metoclopramide) have minimal role due to side effects and limited evidence

V. Outcomes & Follow-Up

• Surgical success defined as resolution/reduction of reflux symptoms, no need for PPIs, and patient satisfaction >85%
• Recurrence rates: ~10–20% at 10 years—higher if crural repair inadequate or defect >4 cm
• Post-op surveillance endoscopy only if new/worsening symptoms—not routine.

VI. Summary of Key Clinical Decision Points

Sources:

1. ACG Clinical Guideline: Management of Hiatal Hernia (Am J Gastroenterol 2022;117:1545–1568)
2. SAGES Guidelines on Antireflux Surgery ( Surg Endosc 2023;37:1529–1560)
3. EHS Clinical Practice Guidelines for Paraesophageal Hernia Repair (Hernia 2021;25:1145–1168)
4. International Helicopter Consensus on Hiatal Hernia Classification (Gut 2020;69:1037–1045)
5. meta-analysis: Laparoscopic vs Open Repair of Paraesophageal Hernia (JAMA Surg 2021;156:897–905)

This review integrates current evidence to guide precision diagnosis and risk-adapted management of hiatal hernia in clinical practice.